Veracyte, Inc. (VCYT) SEC Filings & Earnings Calls

Integration risk and milestone achievement uncertainty.

“Up to $30M in additional cash consideration tied to milestones related to UroAmp publications and reimbursement efforts.”

Payer reimbursement pressure

“We expect to continue to see pressure from payers to limit the utilization of tests, generally, and we believe more payers are deploying cost containment tactics, such as requiring prior authorization, reduction of the payer portion of reimbursement and employing laboratory benefit managers to reduce utilization rates.” · word for word

Revenue recognition estimation risk

“In determining the amount to accrue for a delivered test, we consider factors such as payment history, payer coverage... These estimates require significant judgment by management. Actual results could differ from those estimates and assumptions.” · word for word

Dependence on Medicare and UnitedHealthcare

“Medicare 33%, UnitedHealthcare 13% of total revenue for the three months ended June 30, 2026”

Biopharma revenue declined significantly to $0.8M from $4.3M due to restructuring of Veracyte SAS; ongoing risk from that segment.

“Biopharmaceutical and other revenue was $0.8 million, an expected decrease compared to $4.3 million in the second quarter of 2025 given the restructuring and liquidation proceedings of Veracyte SAS.” · word for word

Share dilution from equity incentive plan; may pressure EPS.

“Approval of 3.5 million share increase in equity plan.”

Payer Concentration

“Medicare and UnitedHealthcare accounted for 47% of total revenue.”

Single-Source Supplier Dependency

“Several of the components of the Company’s sample collection kits and CLIA test reagents, IVD products and associated systems, as well as the systems service and service kits, are obtained from single-source suppliers.” · word for word

Reimbursement Risk

“Changes or implementation of government regulations or reimbursement policies, including under the Protecting Access to Medicare Act of 2014, or PAMA, could result in lower reimbursement rates for our tests.” · word for word

Biopharma revenue decline due to restructuring of Veracyte SAS

“Biopharmaceutical and other revenue was $0.3 million, an expected decrease compared to $3.6 million in the first quarter of 2025 given the restructuring and liquidation proceedings of Veracyte SAS.” · word for word

Equity Dilution from Plan Amendment

“Our Board of Directors has determined that it is in the best interests of the company and our stockholders to seek approval of the Plan Amendment to increase the number of shares that may be issued under the 2023 Plan by 3,500,000 shares.” · word for word

Cybersecurity Risk

“The Board of Directors, in coordination with our Audit Committee, oversees our management of risks arising from cybersecurity threats.” · word for word

Regulatory and Compliance Risk

“The Regulatory and Compliance Committee assists the Board of Directors with oversight of our compliance with healthcare legal and regulatory requirements applicable to our business.” · word for word

PAMA Reimbursement Rate Reduction

“This could result in updated reimbursement rates effective January 1, 2027 through December 31, 2029.” · word for word

Payer Consolidation and Cost Containment

“We expect to continue to see pressure from payers to limit the utilization of tests, generally, and we believe more payers are deploying costs containment tactics, such as pre-authorization and employing laboratory benefit managers to reduce utilization rates.” · word for word

Stark Law and Anti-Kickback Compliance

“We cannot be certain that regulators would find these arrangements to be in compliance with Stark, PORA or similar state laws.” · word for word

Integration Risk from C2i Acquisition

“We may have difficulties integrating C2i's whole-genome, AI-powered technology into our tests, and we may identify flawed algorithms or insufficient or biased datasets, which could adversely impact the reliability of our data and subject us to delays and competitive harm, regulatory action, or legal liability, as well as brand or reputational harm.” · word for word

Geopolitical Risk from Israel Operations

“the ongoing conflict in the Middle East and related political, military and security conditions in and around Israel may disrupt our Israel business activities, facilities, employees and access to electricity, gasoline, or water, as well as disrupt our ability to travel or conduct business in and out of the conflicted area.” · word for word

Biopharmaceutical revenue declining due to Veracyte SAS restructuring.

“Biopharmaceutical and other revenue decreased to $1.0 million from $3.5 million.”

Preliminary results subject to audit adjustment; final audited financials may differ.

“Veracyte’s audited financial statements for the full year ended December 31, 2025 are not yet available... may differ materially from the actual results” · word for word

Guidance excludes contribution from new tests (Prosigna, TrueMRD), which may not materialize as expected.

“excluding the contribution from new tests” · word for word

Restructuring of French subsidiary

“We recorded a $20.5 million non-cash impairment charge during the three months ended June 30, 2025 related to Veracyte SAS.” · word for word

Payer concentration risk

“Medicare and UnitedHealthcare represented 47% of total revenue for Q3 2025.”

Reimbursement risk

“We expect to continue to see pressure from payers to limit the utilization of tests, generally, and we believe more payers are deploying cost containment tactics.” · word for word

Deconsolidation of SAS entity resulted in $6.7M loss, indicating potential operational disruption.

“Including $6.7 million of loss related to the deconsolidation of the SAS entity.” · word for word

Biopharmaceutical and other revenue declined significantly from $3.1M to $0.8M due to SAS restructuring.

“Biopharmaceutical and other revenue was $0.8 million, a decrease compared to $3.1 million in the third quarter of 2024 given the restructuring and liquidation proceedings of Veracyte SAS.” · word for word